Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th ...
Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.
Medicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11
Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...